title: Targeting mTOR signaling for lung cancer therapy.
authors.affiliation: Departments of Hematology & Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA. shi-yong.sun@emoryhealthcare.org
authors.forename: Shi-Yong
authors.initials: SY
authors.lastname: Sun
authors.forename: Haian
authors.initials: H
authors.lastname: Fu
authors.forename: Fadlo R
authors.initials: FR
authors.lastname: Khuri
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D004273:DNA, Neoplasm / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases; D011494:Protein Kinases / Q000235:genetics* / Q000378:metabolism; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D019869:Phosphatidylinositol 3-Kinases; D011494:Protein Kinases; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human